Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	$ (19,023)	$ (21,786)	$ (16,938)
Gain (loss) from discontinued operations	0	691	(1,068)
Net loss from continuing operations	(19,023)	(22,477)	(15,870)
Adjustments to reconcile net loss to net cash used in operating activities from continuing operations:
Depreciation and amortization	300	170	77
Non-cash interest expense	267	163	250
Stock-based compensation expense	1,210	1,731	1,992
Warrant liability revaluation	(3,236)	0	0
Loss on disposal of fixed assets	102	0	0
Shares issued in connection with the fispemifene in-license agreement	0	5,904	0
Deconsolidation of former French Subsidiaries	0	(846)	(641)
Gain on contract settlement	0	(910)	(534)
Recovery on loss on sale of subsidiary	0	(50)	(255)
Derivative liability revaluation	0	(517)	274
Loss on debt extinguishment	0	51	0
Interest on contingent consideration	0	0	242
Other	50	0	131
Changes in operating assets and liabilities from continuing operations:
Accounts receivable	159	(620)	253
Inventories	(194)	61	(341)
Prepaid expenses and other current assets	(466)	(464)	143
Other assets	(13)	2	(52)
Accounts payable	609	(66)	(920)
Deconsolidation of Former French Subsidiaries	0	(2,000)	0
Accrued expenses	(1,276)	2,465	(476)
Accrued compensation	111	160	(140)
Deferred revenue	(1,088)	(574)	1,021
Other liabilities	(154)	(214)	(257)
Net cash used in operating activities from continuing operations	(22,642)	(18,031)	(15,103)
Cash flows from investing activities from continuing operations:
Purchase of fixed assets	(337)	(580)	(573)
Proceeds from sale of subsidiary	0	50	255
Proceeds from the sale of property and equipment	5	0	3,657
Deposit of restricted cash	0	0	(280)
Net cash (used in) provided by investing activities from continuing operations	(332)	(530)	3,059
Cash flows from financing activities from continuing operations:
Issuance of common stock and warrants, net of offering costs	10,869	5,913	16,612
Proceeds from issuance of notes payable	5,000	4,729	0
Repayment of principal on notes payable	(495)	0	0
Proceeds from exercise of warrants	0	0	46
Proceeds from the exercise of stock options	83	0	0
Payment under convertible notes	0	(2,750)	0
Release of restricted cash	10	42	0
Repayment of capital lease obligations	(6)	(27)	(27)
Retirement of restricted stock	0	(42)	0
Net cash provided by financing activities from continuing operations	15,461	7,865	16,631
Cash flows from discontinued operations:
Net cash provided by operating activities of discontinued operations	0	16	38
Net cash provided by investing activities of discontinued operations	0	675	1,650
Net cash provided by discontinued operations	0	691	1,688
Net (decrease) increase in cash and cash equivalents	(7,513)	(10,005)	6,275
Cash and cash equivalents, beginning of period	11,400	21,405	15,130
Cash and cash equivalents, end of period	3,887	11,400	21,405
Supplemental disclosure of cash flow information:
Cash paid for interest	538	193	238
Non-cash investing and financing activities from continuing operations:
Transaction costs for 2016 financing activities	(173)	0	0
Liability incurred in connection with fixed asset purchases	0	(7)	0
Issuance of 486,923 shares of common stock upon conversion of convertible note	0	0	1,737
Release of restricted cash	0	0	(337)
Release of obligations related to short-term loans	0	0	270
July 2025
Non-cash investing and financing activities from continuing operations:
Issuance of common warrants to debtholders	75	0	0
October 2024
Non-cash investing and financing activities from continuing operations:
Issuance of common warrants to debtholders	0	104	0
TopoTarget
Non-cash investing and financing activities from continuing operations:
Issuance of 688,717 shares of common stock to TopoTarget	$ 0	$ 0	$ 1,543